Deadline Soon: Kyverna Therapeutics, Inc. (KYTX) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
Kyverna Therapeutics, Inc. (KYTX)
Company Research
Source: Business Wire
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming February 7, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Kyverna Therapeutics, Inc. (“Kyverna” or the “Company”) (NASDAQ: KYTX) common stock pursuant and/or traceable to the Registration Statement issued in connection with the Company’s February 2024 initial public offering (the “IPO” or the “Offering”).IF YOU ARE AN INVESTOR WHO LOST MONEY ON KYVERNA THERAPEUTICS, INC. (KYTX), CLICK HERE TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT.What Happened?On or about February 8, 2024, Kyverna conducted its IPO selling 14.5 million shares of common stock for $22.00 per share.On June 14, 2024, Kyverna provided an update on its lupus nephritis drug, KYV-101, and published an investor presentation disclosing adverse data regarding one of its clinical trials, despite having previously touted patient improvem
Show less
Read more
Impact Snapshot
Event Time:
KYTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYTX alerts
High impacting Kyverna Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYTX
News
- Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common StockGlobeNewswire
- Kyverna Therapeutics (NASDAQ:KYTX) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.MarketBeat
- Kyverna Therapeutics (NASDAQ:KYTX) was given a new $33.00 price target on by analysts at Morgan Stanley.MarketBeat
- Kyverna Therapeutics Announces Proposed Public Offering of Common StockGlobeNewswire
- Kyverna Therapeutics: Miv-Cel Delivers Breakthrough Data In Stiff Person Syndrome [Seeking Alpha]Seeking Alpha
KYTX
Earnings
- 11/12/25 - Beat
KYTX
Sec Filings
- 12/17/25 - Form FWP
- 12/15/25 - Form 424B5
- 12/15/25 - Form 144
- KYTX's page on the SEC website